Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
暂无分享,去创建一个
G. Comi | P. Sørensen | A. Achiron | T. Olsson | L. Alfredsson | B. Hemmer | H. Wiendl | A. Oturai | S. Schippling | A. Chan | L. Moiola | D. Brassat | K. Myhr | J. Hillert | D. Buck | A. Siva | M. Subramanyam | T. Plavina | T. Berger | P. E. Jensen | H. Hegen | M. Eraksoy | A. Trampe | T. Weber | J. Potts | D. Paes | H. Dib | Deniz Üren | Anne-Kathrin Trampe
[1] H. Wiendl,et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort , 2012, Neurology.
[2] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.
[3] A. Sandrock,et al. Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002) , 2012 .
[4] J. Chapman,et al. Epidemiology of Anti-JCV Antibodies in Israeli Multiple Sclerosis Population (P02.138) , 2012 .
[5] P. Vermersch,et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy , 2012, Journal of Neurology.
[6] A. Sandrock,et al. Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1 , 2011, Annals of neurology.
[7] K. Simon,et al. Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.
[8] I. Koralnik,et al. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.